Analysis of TET۲ Exon ۳ Mutation in a Small Population of Iranian Acute Myeloid Leukemia Patients

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 14

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_PRJMS-29-1_007

تاریخ نمایه سازی: 22 مهر 1405

چکیده مقاله:

Introduction: Aging is an inevitable biological process and is accompanied by several diseases, such as cardiovascular diseases, cancers, and diabetes, which are among worldwide leading causes of death. One of the prevalent cancers among older adults is acute myeloid leukemia (AML), a clonal and heterogeneous blood cancer. Old AML patients have poor prognosis that underlines the importance of finding new biomarkers and treatment for these patients. Ten-eleven translocation ۲ (TET۲) is one of frequently mutated genes in AML patients and specifically, in elderly patients. Therefore, in this exploratory study we aimed to analyze the existence of mutations in the third exon of TET۲ in a small cohort of Iranian AML patients. Methods: Whole blood samples were collected from ۱۶ newly diagnosed AML patients older than ۴۰ years, excluding AML-M۳ patients. DNA was extracted from blood samples and the third exon of TET۲ was amplified using PCR. Sanger sequencing was performed on the amplified exon ۳ samples. Results: The included patients were predominantly composed of M۲ and M۱ FAB subtypes. Sanger sequencing showed no sequence variations in the exon ۳ of TET۲, which may be due to several factors, including sample size, and population variations. Conclusion: Larger cohorts and the implementation of more comprehensive sequencing strategies are required to further elucidate the prognostic value of TET۲ mutations in Iranian AML patients.

کلیدواژه ها:

TET۲ ، Mutation ، Acute myeloid leukemia (AML)

نویسندگان

Ali Fahimioskuei

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

sadaf vahdat

Applied Cell Sciences Division, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Mohammad Ahmadvand

Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran